Loading stock data...

Beryl Drugs Limited

BSE: BERLDRG

BSE
22.72 1.00 (4.60%)

Prev Close

21.72

Open Price

22.77

Volume

3,179

Today Low / High

22.5 / 22.77

52 WK Low / High

20.27 / 43.7

Range

22 - 24

The stock is currently available for trading on the Bombay Stock Exchange (BSE). Its price is 22.72, reflecting a change of 1 (4.60405%). The expected target range on the BSE is 22 - 24. The stock is showing an upward trend on the BSE, making it an appealing option for investors looking for growth in their portfolio.

17 Apr 22.77 -0.22%
16 Apr 23.14 -6.14%
15 Apr 22.01 2.45%
11 Apr 22.65 -2.87%
09 Apr 22.50 0.67%
08 Apr 23.44 -1.88%
07 Apr 21.15 4.02%
04 Apr 23.25 -4.73%
03 Apr 22.72 2.11%
02 Apr 21.80 4.27%
01 Apr 21.05 1.43%
28 Mar 22.22 -5.27%
27 Mar 23.98 -7.34%
26 Mar 24.28 -1.24%
25 Mar 23.45 -0.55%
24 Mar 24.00 -2.83%
21 Mar 24.50 -2.33%
20 Mar 25.38 -7.29%

Beryl Drugs Limited Graph

Beryl Drugs Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges

If you are looking for the target price for Beryl Drugs Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 22.72, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.

Scenario Price Target Range
Bullish Scenario 22.72 22.95 20.65 - 25.24
23.17 18.54 - 27.81
23.40 16.38 - 30.42
Bearish Scenario 22.72 22.49 20.24 - 24.74
22.27 17.81 - 26.72
22.04 15.43 - 28.65

Overview of Beryl Drugs Limited

ISIN

INE415H01017

Industry

Medical - Pharmaceuticals

Vol.Avg

6,053

Market Cap

115,229,024

Last Dividend

0

Official Website

Visit Website

IPO Date

2005-06-14

DCF Diff

N/A

DCF

0

Financial Ratios Every Investor Needs

Stock Rating Details for BERLDRG

Metric Value Recommendation
Overall Rating D+ Strong Sell
DCF Score 1 Strong Sell
ROE Score 1 Strong Sell
ROA Score 1 Strong Sell
Debt-to-Equity (DE) Score 1 Strong Sell
Price-to-Earnings (PE) Score 1 Strong Sell
Price-to-Book (PB) Score 1 Strong Sell

Annual Financial Income Report

Date Revenue Co.Rev GP GPR R&D Expenses G&A Expenses Operating Income Net Income EPS EBITDA NIR
2024-03-31 26.45 Cr 17.77 Cr 8.68 Cr 0.3283 0.00 Cr 0.37 Cr 1.18 Cr 0.77 Cr 1.52 2.66 Cr 0.0291
2023-03-31 26.71 Cr 18.58 Cr 8.13 Cr 0.3043 0.00 Cr 0.36 Cr 1.19 Cr 0.77 Cr 1.51 2.23 Cr 0.0287
2022-03-31 14.45 Cr 10.44 Cr 4.02 Cr 0.2780 0.00 Cr 0.34 Cr -0.65 Cr -0.66 Cr -1.30 0.56 Cr -0.0456
2021-03-31 13.84 Cr 9.46 Cr 4.39 Cr 0.3168 0.00 Cr 0.44 Cr 0.20 Cr 0.24 Cr 0.47 2.07 Cr 0.0173
2020-03-31 12.57 Cr 8.61 Cr 3.95 Cr 0.3146 0.00 Cr 0.39 Cr 0.27 Cr 0.05 Cr 0.09 1.11 Cr 0.0038

Annual Financials Balance Sheet

Date C&C Equ. Tot. Assets Tot. Liab. Stock. Equity Tot. Debt Net Debt Inv. PP&E (Net) Curr. Def. Rev. Non-Curr. Def. Rev. LT Invest. Curr. Liab.
2024-03-31 0.12 Cr 17.49 Cr 8.56 Cr 8.9233 Cr 5.09 Cr 4.97 Cr 1.81 Cr 5.96 Cr 0.18 Cr 0.00 Cr 0.33 Cr 5.7554 Cr
2023-03-31 0.28 Cr 17.51 Cr 9.45 Cr 8.0664 Cr 4.54 Cr 4.26 Cr 1.05 Cr 5.81 Cr 0.13 Cr 0.11 Cr 0.37 Cr 6.3289 Cr
2022-03-31 0.27 Cr 17.82 Cr 10.53 Cr 7.2936 Cr 5.29 Cr 5.02 Cr 2.98 Cr 5.86 Cr 0.19 Cr 0.09 Cr 0.34 Cr 8.4925 Cr
2021-03-31 0.45 Cr 18.65 Cr 10.72 Cr 7.9294 Cr 5.12 Cr 4.67 Cr 2.27 Cr 7.32 Cr 0.10 Cr 0.00 Cr 0.32 Cr 8.2133 Cr
2020-03-31 0.40 Cr 16.91 Cr 9.29 Cr 7.6255 Cr 5.24 Cr 4.84 Cr 1.16 Cr 8.33 Cr 0.16 Cr 0.00 Cr 0.82 Cr 6.6277 Cr

Annual Financials Cash Flow Statement

Date Operating Cash Investing Cash Financing Cash Free Cash Cash Change Cash at End CapEx Income Debt Repay Dividends Inventory
2024-03-31 0.8202 Cr -1.0817 Cr 0.1032 Cr -0.5314 Cr -0.1582 Cr 0.1249 Cr -1.3516 Cr 1.0097 Cr 0.5668 Cr 0.0000 Cr -0.2055 Cr
2023-03-31 2.4804 Cr -1.3017 Cr -1.1671 Cr 0.9169 Cr 0.0117 Cr 0.2831 Cr -1.5635 Cr 0.9839 Cr -0.7516 Cr 0.0000 Cr 1.9236 Cr
2022-03-31 -0.4688 Cr 0.5240 Cr -0.2359 Cr -0.8843 Cr -0.1807 Cr 0.2714 Cr -0.4155 Cr -0.9503 Cr 0.0017 Cr 0.0000 Cr -0.7092 Cr
2021-03-31 0.3385 Cr 0.2550 Cr -0.5377 Cr -0.7144 Cr 0.0558 Cr 0.4521 Cr -1.0529 Cr 0.3480 Cr -0.1113 Cr 0.0000 Cr -1.1116 Cr
2020-03-31 0.1848 Cr -1.5547 Cr 1.6665 Cr -1.6904 Cr 0.2965 Cr 0.3963 Cr -1.8752 Cr 0.1579 Cr 1.9875 Cr 0.0000 Cr -0.3935 Cr

Quarterly Financial Income Report

Date Revenue Co.Rev GP GPR Operating Income Net Income EPS EBITDA NIR
2024-12-31 5.31 Cr 1.83 Cr 3.48 Cr 0.6546 0.28 Cr 0.05 Cr 0.10 0.59 Cr 0.0098
2024-09-30 5.61 Cr 2.68 Cr 2.93 Cr 0.5225 0.23 Cr 0.01 Cr 0.01 0.57 Cr 0.0012
2024-06-30 6.25 Cr 4.23 Cr 2.02 Cr 0.3230 0.67 Cr 0.37 Cr 0.73 0.99 Cr 0.0589
2024-03-31 3.21 Cr 3.83 Cr -0.62 Cr -0.1938 -0.29 Cr -0.35 Cr -0.68 0.03 Cr -0.1082
2023-12-31 7.66 Cr 4.06 Cr 3.60 Cr 0.4700 0.49 Cr 0.31 Cr 0.61 0.80 Cr 0.0406

Quarterly Financials Balance Sheet

Date Cash & Equiv. Short-Term Inv. Cash & Short-Term Net Receivables Inventory Total Curr. Assets PP&E (Net) Total Assets Total Liabilities
2024-09-30 0.08 Cr 0.19 Cr 0.27 Cr 0.00 Cr 1.26 Cr 8.96 Cr 7.06 Cr 17.00 Cr 7.70 Cr
2024-03-31 0.12 Cr 0.10 Cr 0.22 Cr 7.59 Cr 1.81 Cr 10.22 Cr 5.96 Cr 17.49 Cr 8.56 Cr
2023-12-31 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr
2023-09-30 0.25 Cr 0.92 Cr 1.18 Cr 0.00 Cr 1.03 Cr 11.73 Cr 6.01 Cr 19.28 Cr 10.26 Cr
2023-06-30 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr 0.00 Cr

Quarterly Financials Cash Flow Statement

Date Net Income Operating Cash Flow Investing Cash Flow Financing Cash Flow Net Cash Change Cash at End Cash at Beginning CapEx Free Cash Flow
2023-12-31 0.31 Cr 0.62 Cr 0.00 Cr 0.00 Cr 0.62 Cr 1.06 Cr 0.44 Cr 0.00 Cr 0.62 Cr
2023-09-30 0.27 Cr 0.27 Cr 0.00 Cr 0.00 Cr 0.27 Cr 0.44 Cr 0.17 Cr 0.00 Cr 0.27 Cr
2023-06-30 0.53 Cr 0.53 Cr 0.00 Cr 0.00 Cr 0.25 Cr 0.53 Cr 0.28 Cr 0.00 Cr 0.53 Cr
2023-03-31 0.06 Cr 0.06 Cr 0.00 Cr 0.00 Cr 0.06 Cr 0.28 Cr 0.22 Cr 0.00 Cr 0.06 Cr
2022-12-31 0.14 Cr 0.14 Cr 0.00 Cr 0.00 Cr -0.24 Cr 0.14 Cr 0.39 Cr 0.00 Cr 0.14 Cr

Splits History

Date Label Split Ratio
No split history data available.

Similar Stocks: Medical - Pharmaceuticals

Company Name Symbol Price Market Cap Volume
MedPlus Health Services Limited MEDPLUS ₹795.30 ₹95,148,896,700.00 ₹151,791.00

Key Executives

Chief Financial Officer
Mr. Ashish Baraskar

Gender: male

Year Born:

MD & Executive Director
Mr. Sanjay Sethi

Gender: male

Year Born: 1963

Compliance Officer & Company Secretary
Ms. Neha Sharma CS

Gender: female

Year Born:

FAQs about Beryl Drugs Limited

Who is the CEO of the company?

The CEO is Mr. Sanjay Sethi.

What is the current market price of the stock?

The current price is ₹22.72.

What is the 52-week price range?

The range is ₹20.27-43.7.

What is the market capitalization of the company?

The market capitalization is ₹11.52 crores.

What is the Price-to-Earnings (P/E) ratio?

The P/E ratio is 148.62.

Which sector does the company belong to?

The company operates in the Healthcare sector.

What does the company do?

Overview of Beryl Drugs Limited (ISIN: INE415H01017) is a leading Medical - Pharmaceuticals in India. With a market capitalization of ₹11.52 crores and an average daily volume of 6,053 shares, it operates in the Medical - Pharmaceuticals. The company last declared a dividend of ₹0.

Welcome to the Investing and Trading Information platform: InvesTrack.in

Note: This platform is for educational and informational purposes only. Do not consider anything as financial advice.

QUICK LINKS

Home
About us
Contact us
Privacy Policy
Disclaimer
Sitemap
Investing
Trading
Top Brokers
Tools
Live Analysis

STAY CONNECTED

Follow Us On Social Media
Get Latest Update On Social Media
Facebook Instagram Twitter

General Disclaimer: InvesTrack is an educational platform and not any type of investment advisory platform. Our Blog and videos are based on countless hours of research and experience, which you can use as a guide for your research purposes. None of our content should be considered a piece of investment advice. Earning Disclosure: InvesTrack is a community supported platform. We may earn a commission when you make a purchase through one of our links at no extra cost to you. Note: We are not SEBI Registered Advisors. This website is purely for training and educational purposes. We shall not be responsible for your profit or loss.

© Copyright 2024 - 2025 | InvesTrack